Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles

Cancer Immunology, Immunotherapy

Volumn 59, Issue 11, 2010, Pages 1685-1696

  Pejawar Gaddy, Sharmila ^b   Rajawat, Yogendra ^a   Hilioti, Zoe ^a   Xue, Jia ^b   Gaddy, Daniel F ^b   Finn, Olivera J ^b   Viscidi, Raphael P ^c   Bossis, Ioannis ^a  

^a UNIVERSITY OF MARYLAND   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chimeric VLPs Immunotherapy; MUC1; Papillomaviruses

Indexed keywords

BOVINE PAPILLOMA VIRUS L1 PROTEIN; BOVINE PAPILLOMA VIRUS LIKE PARTICLE VACCINE; CANCER VACCINE; MUCIN 1; UNCLASSIFIED DRUG; VIRUS PROTEIN;

AMINO ACID COMPOSITION; AMINO ACID SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACULOVIRUS EXPRESSION SYSTEM; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CELL ACTIVATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; COVALENT BOND; DENDRITIC CELL; DISULFIDE BOND; DRUG CONJUGATION; DRUG POTENTIATION; DRUG SPECIFICITY; GENE INSERTION; GROWTH INHIBITION; HYBRIDOMA; INSECT CELL; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; OXIDATION REDUCTION STATE; PAPILLOMA VIRUS; PRIORITY JOURNAL; STATIC ELECTRICITY; T LYMPHOCYTE; TANDEM REPEAT; TUMOR REJECTION; VIRUS PARTICLE;

ANIMALS; CANCER VACCINES; CAPSID PROTEINS; CATTLE; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOMA, T-CELL; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUCIN-1; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS VACCINES; PEPTIDE FRAGMENTS; PEPTIDES; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VIRION;

EID: 77958053612     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-010-0895-0     Document Type: Article

References (41)

1. Li Y, Cozzi PJ (2007) MUC1 is a promising therapeutic target for prostate cancer therapy. Curr Cancer Drug Targets 7:259-271
2. Vlad AM, Kettel JC, Alajez NM et al (2004) MUC1 immuno-biology: from discovery to clinical applications. Adv Immunol 82:249-293
3. North S, Butts C (2005) Vaccination with BLP25 liposome vaccine to treat non-small cell lung and prostate cancers. Expert Rev Vaccines 4:249-257
4. Dorn DC, Lawatscheck R, Zvirbliene A et al (2008) Cellular and humoral immunogenicity of hamster polyomavirus-derived viruslike particles harboring a mucin 1 cytotoxic T-cell epitope. Viral Immunol 21:12-27
5. Grgacic EV, Anderson DA (2006) Virus-like particles: passport to immune recognition. Methods 40:60-65
6. Fifis T, Gamvrellis A, Crimeen-Irwin B et al (2004) Size-dependent immunogenicity: therapeutic and protective properties of nano-vaccines against tumors. J Immunol 173:3148-3154
7. Dickgreber N, Stoitzner P, Bai Y et al (2009) Targeting antigen to MHC class II molecules promotes efficient cross-presentation and enhances immunotherapy. J Immunol 182:1260-1269
8. Boisgérault F, Morón G, Leclerc C (2002) Virus-like particles: a new family of delivery systems. Expert Rev Vaccines 1:101-109
9. Chackerian B, Lowy DR, Schiller JT (2001) Conjugation of a self-antigen to papillomavirus-like particles allows for efficient induction of protective autoantibodies. J Clin Invest 108:415-423
10. Peacey M, Wilson S, Baird MA et al (2007) Versatile RHDV virus-like particles: incorporation of antigens by genetic modification and chemical conjugation. Biotechnol Bioeng 98:968-977
11. Stubenrauch K, Gleiter S, Brinkmann U (2001) Conjugation of an antibody Fv fragment to a virus coat protein: cell-specific targeting of recombinant polyoma-virus-like particles. Biochem J 356:867-873
12. Vlad AM, Muller S, Cudic M et al (2002) Complex carbohydrates are not removed during processing of glycoproteins by dendritic cells: processing of tumor antigen MUC1 glycopeptides for presentation to major histocompatibility complex class II-restricted T cells. J Exp Med 196:1435-1446
13. Alajez NM, Schmielau J, Alter MD et al (2005) Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution. Blood 105:4583-4589
14. Turner MS, Cohen PA, Finn OJ (2007) Lack of effective MUC1 tumor antigen-specific immunity in MUC1-transgenic mice results from a Th/T regulatory cell imbalance that can be corrected by adoptive transfer of wild-type Th cells. J Immunol 178:2787-2793
15. Soares MM, Mehta V, Finn OJ (2001) Three different vaccines based on the 140-amino acid MUC1 peptide with seven tandemly repeated tumor-specific epitopes elicit distinct immune effector mechanisms in wild-type versus MUC1-transgenic mice with different potential for tumor rejection. J Immunol 166:6555-6563
16. Devêvre E, Romero P, Mahnke YD (2006) LiveCount assay: concomitant measurement of cytolytic activity and phenotypic characterisation of CD8(+) T-cells by flow cytometry. J Immunol Methods 311:31-46
17. Goriely S, Goldman M (2008) Interleukin-12 family members and the balance between rejection and tolerance. Curr Opin Organ Transplant 13:4-9
18. Aktas E, Kucuksezer UC, Bilgic S et al (2009) Relationship between CD107a expression and cytotoxic activity. Cell Immuno1 254:149-154
19. Acres B, Limacher JM (2005) MUC1 as a target antigen for cancer immunotherapy. Expert Rev Vaccines 4:493-502
20. Byrd JC, Bresalier RS (2004) Mucins and mucin binding proteins in colorectal cancer. Cancer Metastasis Rev 23:77-99
21. Karsten U, von Mensdorff-Pouilly S, Goletz S (2005) What makes MUC1 a tumor antigen? Tumour Biol 26:217-220
22. Brockhausen I, Yang JM, Burchell J et al (1995) Mechanisms underlying aberrant glycosylation of MUC1 mucin in breast cancer cells. Eur J Biochem 233:607-617
23. Kotera Y, Fontenot JD, Pecher G et al (1994) Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic, and colon cancer patients. Cancer Res 54:2856-2860
24. McKolanis JR, Finn OJ (2000) Analysis of the frequency of MHC-unrestricted MUC1-specific cytotoxic T-cells in peripheral blood by limiting dilution assay. Methods Mol Biol 125:463-470
25. von Mensdorff-Pouilly S, Vennegoor C, Hilgers J (2002) Detection of humoral immune responses to mucins. Methods Mol Biol 125:495-500
26. Bontkes HJ, Ruizendaal JJ, Kramer D et al (2005) Plasmacytoid dendritic cells are present in cervical carcinoma and become activated by human papillomavirus type 16 virus-like particles. Gynecol Oncol 96:897-901
27. Rudolf MP, Fausch SC, Da Silva DM et al (2001) Human dendritic cells are activated by chimeric human papillomavirus type-16 virus-like particles and induce epitope-specific human T cell responses in vitro. J Immunol 166:5917-5924
28. Yang R, Murillo FM, Cui H et al (2004) Papillomavirus-like particles stimulate murine bone marrow-derived dendritic cells to produce alpha interferon and Th1 immune responses via MyD88. J Virol 78:11152-11160
29. Andreasson K, Tegerstedt K, Eriksson M et al (2009) Murine pneumotropic virus chimeric Her2/neu virus-like particles as prophylactic and therapeutic vaccines against Her2/neu expressing tumors. Int J Cancer 124:150-156
30. Tegerstedt K, Franzén A, Ramqvist T, Dalianis T (2007) Dendritic cells loaded with polyomavirus VP1/VP2Her2 virus-like particles efficiently prevent outgrowth of a Her2/neu expressing tumor. Cancer Immunol Immunother 56:1335-1344
31. Gedvilaite A, Dorn DC, Sasnauskas K et al (2006) Virus-like particles derived from major capsid protein VP1 of different polyomaviruses differ in their ability to induce maturation in human dendritic cells. Virology 354:252-260
32. Yan M, Peng J, Jabbar IA et al (2004) Despite differences between dendritic cells and Langerhans cells in the mechanism of papillomavirus-like particle antigen uptake, both cells cross-prime T cells. Virology 324:297-310
33. Schiller JT, Castellsagué X, Villa LL et al (2008) An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine (Suppl) 10: K53-K61
34. Trus BL, Roden RB, Greenstone HL et al (1997) Novel structural features of bovine papillomavirus capsid revealed by a three-dimensional reconstruction to 9 A resolution. Nat Struct Biol 4:413-420
35. Buck CB, Cheng N, Thompson CD et al (2008) Arrangement of L2 within the papillomavirus capsid. J Virol 82:5190-5197
36. Roy P, Noad R (2008) Virus-like particles as a vaccine delivery system: myths and facts. Hum Vaccin 4:5-12
37. Miyamura K, Kajigaya S, Momoeda M et al (1994) Parvovirus particles as platforms for protein presentation. Proc Natl Acad Sci USA 91:8507-8511
38. Müller M, Zhou J, Reed TD et al (1997) Chimeric papillomavirus-like particles. Virology 234:93-111
39. Tindle RW, Herd K, Londono P et al (1994) Chimeric hepatitis B core antigen particles containing B-and Th-epitopes of human papillomavirus type 16 E7 protein induce specific antibody and T-helper responses in immunised mice. Virology 200:547-557
40. Wagner R, Deml L, Schirmbeck R et al (1996) Construction, expression, and immunogenicity of chimeric HIV-1 virus-like particles. Virology 220:128-140
41. Chen XS, Garcea RL (2000) Goldberg I et al. (2000) Structure of small virus-like particles assembled from the L1 protein of human papillomavirus 16. Mol Cell 5:557-567